136 related articles for article (PubMed ID: 31750417)
1. Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia.
Mau LW; Meyer C; Burns LJ; Saber W; Steinert P; Vanness DJ; Preussler JM; Silver A; Leppke S; Murphy EA; Denzen E
JNCI Cancer Spectr; 2019 Dec; 3(4):pkz048. PubMed ID: 31750417
[TBL] [Abstract][Full Text] [Related]
2. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.
Mau LW; Preussler JM; Meyer CL; Senneka MK; Wallerstedt S; Steinert P; Khera N; Saber W
Transplant Cell Ther; 2022 Dec; 28(12):852-858. PubMed ID: 36170959
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD; Brazauskas R; He N; Li Y; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Hashmi S; Parsons S; Wood WA; Steinberg A; Freytes CO; Dandoy CE; Marks DI; Lazarus HM; Abdel-Azim H; Bitan M; Diaz MA; Olsson RF; Gergis U; Seber A; Wirk B; LeMaistre CF; Ustun C; Duncan C; Rizzieri D; Szwajcer D; Fagioli F; Frangoul H; Knight JM; Kamble RT; Mehta P; Schears R; Satwani P; Pulsipher MA; Aplenc R; Saber W
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1747-1756. PubMed ID: 32464284
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
5. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
Hahn T; McCarthy PL; Hassebroek A; Bredeson C; Gajewski JL; Hale GA; Isola LM; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
J Clin Oncol; 2013 Jul; 31(19):2437-49. PubMed ID: 23715573
[TBL] [Abstract][Full Text] [Related]
6. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.
Ustun C; Courville EL; DeFor T; Dolan M; Randall N; Yohe S; Bejanyan N; Warlick E; Brunstein C; Weisdorf DJ; Linden MA
Biol Blood Marrow Transplant; 2016 Apr; 22(4):669-675. PubMed ID: 26551635
[TBL] [Abstract][Full Text] [Related]
7. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings.
Dunavin N; Mau LW; Meyer CL; Divine C; Abdallah AO; Leppke S; D'Souza A; Denzen E; Saber W; Burns LJ; Ganguly S
Biol Blood Marrow Transplant; 2020 Apr; 26(4):805-813. PubMed ID: 31917269
[TBL] [Abstract][Full Text] [Related]
8. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
[TBL] [Abstract][Full Text] [Related]
9. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
10. Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival.
Herr MM; Rehman S; Zhang Y; Ho CM; Chen GL; Ross M; Hillengass J; Jacobson H; McKenzie R; Farrell K; Maqsood A; McCarthy PL; Hahn T
Transplant Cell Ther; 2021 Oct; 27(10):875.e1-875.e9. PubMed ID: 34216792
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
12. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.
Huang LW; Sheng Y; Andreadis C; Logan AC; Mannis GN; Smith CC; Gaensler KML; Martin TG; Damon LE; Steinman MA; Huang CY; Olin RL
Biol Blood Marrow Transplant; 2020 Jan; 26(1):189-196. PubMed ID: 31493541
[TBL] [Abstract][Full Text] [Related]
13. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
14. Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.
Sugidono M; Lo M; Young R; Rosario K; Jung Y; Huang CY; Sheng Y; Huang LW; Olin RL
Transplant Cell Ther; 2021 Apr; 27(4):344.e1-344.e5. PubMed ID: 33836888
[TBL] [Abstract][Full Text] [Related]
15. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
16. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
17. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
18. Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era.
Hong S; Rybicki L; Corrigan D; Hamilton BK; Sobecks R; Kalaycio M; Gerds AT; Dean RM; Hill BT; Pohlman B; Jagadeesh D; Anwer F; Majhail NS
Hematol Oncol Stem Cell Ther; 2021 Dec; 14(4):318-326. PubMed ID: 33301747
[TBL] [Abstract][Full Text] [Related]
19. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.
Ustun C; Kim S; Chen M; Beitinjaneh AM; Brown VI; Dahi PB; Daly A; Diaz MA; Freytes CO; Ganguly S; Hashmi S; Hildebrandt GC; Lazarus HM; Nishihori T; Olsson RF; Page KM; Papanicolaou G; Saad A; Seo S; William BM; Wingard JR; Wirk B; Yared JA; Perales MA; Auletta JJ; Komanduri KV; Lindemans CA; Riches ML
Blood Adv; 2019 Sep; 3(17):2525-2536. PubMed ID: 31471322
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
